Legal status
Legal status
  • [5-(4-butylphenyl)-1-pentylpyrrol-3-yl]-naphthalen-1-ylmethanone
PubChem CID
Chemical and physical data
Molar mass423.600 g·mol−1
3D model (JSmol)
  • InChI=1S/C30H33NO/c1-3-5-9-20-31-22-26(21-29(31)25-18-16-23(17-19-25)11-6-4-2)30(32)28-15-10-13-24-12-7-8-14-27(24)28/h7-8,10,12-19,21-22H,3-6,9,11,20H2,1-2H3 checkY

JWH-371 ([5-(4-butylphenyl)-1-pentylpyrrol-3-yl]-naphthalen-1-ylmethanone) is a synthetic cannabinoid from the naphthoylpyrrole family which acts as an agonist of the CB1 (Ki = 42 ± 1nM) and CB2 (Ki = 64 ± 2nM) receptors, binding ~1.5 times stronger to the CB1 receptor than the CB2 receptor. JWH-371 was first synthesized in 2006 by John W. Huffman and colleagues to examine the nature of ligand binding to the CB1 receptor.[1]


In the United States JWH-371 is not federally scheduled, although some states have passed legislation banning the sale, possession, and manufacture of JWH-371.[2][3][4][5]

In Canada, JWH-371 and other naphthoylpyrrole-based cannabinoids are Schedule II controlled substances under the Controlled Drugs and Substances Act.[citation needed]

In the United Kingdom, JWH-371 and other naphthoylpyrrole-based cannabinoids are considered Class B drugs under the Misuse of Drugs Act 1971.[citation needed]

See also


  1. ^ Huffman JW, Padgett LW, Isherwood ML, Wiley JL, Martin BR (October 2006). "1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors". Bioorganic & Medicinal Chemistry Letters. 16 (20): 5432–5. doi:10.1016/j.bmcl.2006.07.051. PMID 16889960.
  2. ^ 21 U.S.C. § 812: Schedules of controlled substances
  3. ^ "The 2020 Florida Statutes". www.leg.state.fl.us. Retrieved 20 August 2021.
  4. ^ "Arizona Revised Statutes Title 13. Criminal Code § 13-3401". www.azleg.gov. Retrieved 20 August 2021.
  5. ^ "California Code, Health and Safety Code - HSC § 11357.5". Findlaw.